Samaglutide
Contact Us →Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, originally developed for the management of type 2 diabetes. It has recently gained significant attention in research focused on weight regulation, metabolic syndrome, and appetite control.
Studies have shown that Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways. It may also play a role in cardiovascular protection, hepatic lipid metabolism, and long-term weight management.
Key Research Areas:
-
GLP-1 receptor activation and glucose homeostasis
-
Appetite suppression and caloric intake reduction
-
Body weight regulation and obesity research
-
Cardiovascular risk reduction
-
Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome
